Exact Mass: 415.2603596000001
Exact Mass Matches: 415.2603596000001
Found 500 metabolites which its exact mass value is equals to given mass value 415.2603596000001,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Salmeterol
C25H37NO4 (415.27224420000005)
Salmeterol is only found in individuals that have used or taken this drug. It is a long-acting beta2-adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD. Salmeterols long, lipophilic side chain binds to exosites near beta(2)-receptors in the lungs and on bronchiolar smooth muscle, allowing the active portion of the molecule to remain at the receptor site, continually binding and releasing. Beta(2)-receptor stimulation in the lung causes relaxation of bronchial smooth muscle, bronchodilation, and increased bronchial airflow. R - Respiratory system > R03 - Drugs for obstructive airway diseases > R03A - Adrenergics, inhalants > R03AC - Selective beta-2-adrenoreceptor agonists D019141 - Respiratory System Agents > D018927 - Anti-Asthmatic Agents > D001993 - Bronchodilator Agents C78273 - Agent Affecting Respiratory System > C29712 - Anti-asthmatic Agent > C319 - Bronchodilator D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D000322 - Adrenergic Agonists D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents Salmeterol (GR33343X) is a potent and selective human β2 adrenoceptor agonist. Salmeterol shows potent stimulation of cAMP accumulation in CHO cells expressing human β2, β1 and β3 adrenoceptors with pEC50s of 9.6, 6.1, and 5.9, respectively[1].
Bimatoprost
C25H37NO4 (415.27224420000005)
Bimatoprost ophthalmic solution is a topical medication used for controlling the progression of glaucoma or ocular hypertension, by reducing intraocular pressure. It is a prostaglandin analogue that works by increasing the outflow of aqueous fluid from the eyes. It binds to the prostanoid FP receptor. S - Sensory organs > S01 - Ophthalmologicals > S01E - Antiglaucoma preparations and miotics > S01EE - Prostaglandin analogues C78283 - Agent Affecting Organs of Special Senses > C29705 - Anti-glaucoma Agent D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents C78568 - Prostaglandin Analogue
(4Z)-3-Hydroxytetradec-4-enedioylcarnitine
(4Z)-3-Hydroxytetradec-4-enedioylcarnitine is an acylcarnitine. More specifically, it is an (4Z)-3-hydroxytetradec-4-enedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (4Z)-3-Hydroxytetradec-4-enedioylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (4Z)-3-Hydroxytetradec-4-enedioylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(9E)-3-Hydroxytetradec-5-enedioylcarnitine
(9E)-3-Hydroxytetradec-5-enedioylcarnitine is an acylcarnitine. More specifically, it is an (9E)-3-hydroxytetradec-5-enedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (9E)-3-Hydroxytetradec-5-enedioylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (9E)-3-Hydroxytetradec-5-enedioylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(2E)-5-Hydroxytetradec-2-enedioylcarnitine
(2E)-5-Hydroxytetradec-2-enedioylcarnitine is an acylcarnitine. More specifically, it is an (2E)-5-hydroxytetradec-2-enedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (2E)-5-Hydroxytetradec-2-enedioylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (2E)-5-Hydroxytetradec-2-enedioylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(5Z)-3-Hydroxytetradec-5-enedioylcarnitine
(5Z)-3-Hydroxytetradec-5-enedioylcarnitine is an acylcarnitine. More specifically, it is an (5Z)-3-hydroxytetradec-5-enedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (5Z)-3-Hydroxytetradec-5-enedioylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (5Z)-3-Hydroxytetradec-5-enedioylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(7Z)-3-Hydroxytetradec-7-enedioylcarnitine
(7Z)-3-Hydroxytetradec-7-enedioylcarnitine is an acylcarnitine. More specifically, it is an (7Z)-3-hydroxytetradec-7-enedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (7Z)-3-Hydroxytetradec-7-enedioylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (7Z)-3-Hydroxytetradec-7-enedioylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
N-Docosahexaenoyl Serine
C25H37NO4 (415.27224420000005)
N-docosahexaenoyl serine belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is a Docosahexaenoyl amide of Serine. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Docosahexaenoyl Serine is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Docosahexaenoyl Serine is therefore classified as a very long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.
7-[(1R,2R,3R,5S)-3,5-Dihydroxy-2-[(3S)-3-hydroxy-5-phenylpent-1-enyl]cyclopentyl]-N-ethylhept-5-enamide
C25H37NO4 (415.27224420000005)
N-Demethyl Mifepristone
C28H33NO2 (415.25111580000004)
N-(R)-[2-(Hydroxyaminocarbonyl)methyl]-4-methylpentanoyl-L-t-butyl-alanyl-L-alanine, 2-aminoethyl Amide
C19H37N5O5 (415.27945520000003)
2-(10-hydroxy-3,7,9,11-tetramethyltrideca-2,5,7,11-tetraenyl)-5,6-dimethoxy-3-methyl-1H-pyridin-4-one
C25H37NO4 (415.27224420000005)
methyl 4-((E)-2-acetyl-4-oxotridec-1-enyl)-6-propylnicotinate
C25H37NO4 (415.27224420000005)
(S,S)-ciliatamide B|ciliatamide B|N-methyl-((S)-azepan-2-one-3-ylamino-(S)-oxo-3-phenylpropan-2-yl)octanamide
Salmeterol
C25H37NO4 (415.27224420000005)
R - Respiratory system > R03 - Drugs for obstructive airway diseases > R03A - Adrenergics, inhalants > R03AC - Selective beta-2-adrenoreceptor agonists D019141 - Respiratory System Agents > D018927 - Anti-Asthmatic Agents > D001993 - Bronchodilator Agents C78273 - Agent Affecting Respiratory System > C29712 - Anti-asthmatic Agent > C319 - Bronchodilator D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D000322 - Adrenergic Agonists D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents Salmeterol (GR33343X) is a potent and selective human β2 adrenoceptor agonist. Salmeterol shows potent stimulation of cAMP accumulation in CHO cells expressing human β2, β1 and β3 adrenoceptors with pEC50s of 9.6, 6.1, and 5.9, respectively[1].
Bimatoprost
C25H37NO4 (415.27224420000005)
S - Sensory organs > S01 - Ophthalmologicals > S01E - Antiglaucoma preparations and miotics > S01EE - Prostaglandin analogues C78283 - Agent Affecting Organs of Special Senses > C29705 - Anti-glaucoma Agent D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents C78568 - Prostaglandin Analogue
Ala Ala Arg Val
Ala Ala Val Arg
Ala Gly Ile Arg
Ala Gly Leu Arg
Ala Gly Arg Ile
Ala Gly Arg Leu
Ala Ile Gly Arg
Ala Ile Asn Val
Ala Ile Arg Gly
Ala Ile Val Asn
Ala Lys Pro Thr
Ala Lys Thr Pro
Ala Lys Val Val
C19H37N5O5 (415.27945520000003)
Ala Leu Gly Arg
Ala Leu Asn Val
Ala Leu Arg Gly
Ala Leu Val Asn
Ala Asn Ile Val
Ala Asn Leu Val
Ala Asn Val Ile
Ala Asn Val Leu
Ala Pro Lys Thr
Ala Pro Thr Lys
Ala Gln Val Val
Ala Arg Ala Val
Ala Arg Gly Ile
Ala Arg Gly Leu
Ala Arg Ile Gly
Ala Arg Leu Gly
Ala Arg Val Ala
Ala Thr Lys Pro
Ala Thr Pro Lys
Ala Val Ala Arg
Ala Val Ile Asn
Ala Val Lys Val
C19H37N5O5 (415.27945520000003)
Ala Val Leu Asn
Ala Val Asn Ile
Ala Val Asn Leu
Ala Val Gln Val
Ala Val Arg Ala
Ala Val Val Lys
C19H37N5O5 (415.27945520000003)
Ala Val Val Gln
Gly Ala Ile Arg
Gly Ala Leu Arg
Gly Ala Arg Ile
Gly Ala Arg Leu
Gly Ile Ala Arg
Gly Ile Ile Asn
Gly Ile Lys Val
C19H37N5O5 (415.27945520000003)
Gly Ile Leu Asn
Gly Ile Asn Ile
Gly Ile Asn Leu
Gly Ile Gln Val
Gly Ile Arg Ala
Gly Ile Val Lys
C19H37N5O5 (415.27945520000003)
Gly Ile Val Gln
Gly Lys Ile Val
C19H37N5O5 (415.27945520000003)
Gly Lys Leu Val
C19H37N5O5 (415.27945520000003)
Gly Lys Val Ile
C19H37N5O5 (415.27945520000003)
Gly Lys Val Leu
C19H37N5O5 (415.27945520000003)
Gly Leu Ala Arg
Gly Leu Ile Asn
Gly Leu Lys Val
C19H37N5O5 (415.27945520000003)
Gly Leu Leu Asn
Gly Leu Asn Ile
Gly Leu Asn Leu
Gly Leu Gln Val
Gly Leu Arg Ala
Gly Leu Val Lys
C19H37N5O5 (415.27945520000003)
Gly Leu Val Gln
Gly Asn Ile Ile
Gly Asn Ile Leu
Gly Asn Leu Ile
Gly Asn Leu Leu
Gly Gln Ile Val
Gly Gln Leu Val
Gly Gln Val Ile
Gly Gln Val Leu
Gly Arg Ala Ile
Gly Arg Ala Leu
Gly Arg Ile Ala
Gly Arg Leu Ala
Gly Val Ile Lys
C19H37N5O5 (415.27945520000003)
Gly Val Ile Gln
Gly Val Lys Ile
C19H37N5O5 (415.27945520000003)
Gly Val Lys Leu
C19H37N5O5 (415.27945520000003)
Gly Val Leu Lys
C19H37N5O5 (415.27945520000003)
Gly Val Leu Gln
Gly Val Gln Ile
Gly Val Gln Leu
Ile Ala Gly Arg
Ile Ala Asn Val
Ile Ala Arg Gly
Ile Ala Val Asn
Ile Gly Ala Arg
Ile Gly Ile Asn
Ile Gly Lys Val
C19H37N5O5 (415.27945520000003)
Ile Gly Leu Asn
Ile Gly Asn Ile
Ile Gly Asn Leu
Ile Gly Gln Val
Ile Gly Arg Ala
Ile Gly Val Lys
C19H37N5O5 (415.27945520000003)
Ile Gly Val Gln
Ile Ile Gly Asn
Ile Ile Asn Gly
Ile Lys Gly Val
C19H37N5O5 (415.27945520000003)
Ile Lys Val Gly
C19H37N5O5 (415.27945520000003)
Ile Leu Gly Asn
Ile Leu Asn Gly
Ile Asn Ala Val
Ile Asn Gly Ile
Ile Asn Gly Leu
Ile Asn Ile Gly
Ile Asn Leu Gly
Ile Asn Val Ala
Ile Gln Gly Val
Ile Gln Val Gly
Ile Arg Ala Gly
Ile Arg Gly Ala
Ile Val Ala Asn
Ile Val Gly Lys
C19H37N5O5 (415.27945520000003)
Ile Val Gly Gln
Ile Val Lys Gly
C19H37N5O5 (415.27945520000003)
Ile Val Asn Ala
Ile Val Gln Gly
Lys Ala Pro Thr
Lys Ala Thr Pro
Lys Ala Val Val
C19H37N5O5 (415.27945520000003)
Lys Gly Ile Val
C19H37N5O5 (415.27945520000003)
Lys Gly Leu Val
C19H37N5O5 (415.27945520000003)
Lys Gly Val Ile
C19H37N5O5 (415.27945520000003)
Lys Gly Val Leu
C19H37N5O5 (415.27945520000003)
Lys Ile Gly Val
C19H37N5O5 (415.27945520000003)
Lys Ile Val Gly
C19H37N5O5 (415.27945520000003)
Lys Leu Gly Val
C19H37N5O5 (415.27945520000003)
Lys Leu Val Gly
C19H37N5O5 (415.27945520000003)
Lys Pro Ala Thr
Lys Pro Thr Ala
Lys Thr Ala Pro
Lys Thr Pro Ala
Lys Val Ala Val
C19H37N5O5 (415.27945520000003)
Lys Val Gly Ile
C19H37N5O5 (415.27945520000003)
Lys Val Gly Leu
C19H37N5O5 (415.27945520000003)
Lys Val Ile Gly
C19H37N5O5 (415.27945520000003)
Lys Val Leu Gly
C19H37N5O5 (415.27945520000003)
Lys Val Val Ala
C19H37N5O5 (415.27945520000003)
Leu Ala Gly Arg
Leu Ala Asn Val
Leu Ala Arg Gly
Leu Ala Val Asn
Leu Gly Ala Arg
Leu Gly Ile Asn
Leu Gly Lys Val
C19H37N5O5 (415.27945520000003)
Leu Gly Leu Asn
Leu Gly Asn Ile
Leu Gly Asn Leu
Leu Gly Gln Val
Leu Gly Arg Ala
Leu Gly Val Lys
C19H37N5O5 (415.27945520000003)
Leu Gly Val Gln
Leu Ile Gly Asn
Leu Ile Asn Gly
Leu Lys Gly Val
C19H37N5O5 (415.27945520000003)
Leu Lys Val Gly
C19H37N5O5 (415.27945520000003)
Leu Leu Gly Asn
Leu Leu Asn Gly
Leu Asn Ala Val
Leu Asn Gly Ile
Leu Asn Gly Leu
Leu Asn Ile Gly
Leu Asn Leu Gly
Leu Asn Val Ala
Leu Gln Gly Val
Leu Gln Val Gly
Leu Arg Ala Gly
Leu Arg Gly Ala
Leu Val Ala Asn
Leu Val Gly Lys
C19H37N5O5 (415.27945520000003)
Leu Val Gly Gln
Leu Val Lys Gly
C19H37N5O5 (415.27945520000003)
Leu Val Asn Ala
Leu Val Gln Gly
Asn Ala Ile Val
Asn Ala Leu Val
Asn Ala Val Ile
Asn Ala Val Leu
Asn Gly Ile Ile
Asn Gly Ile Leu
Asn Gly Leu Ile
Asn Gly Leu Leu
Asn Ile Ala Val
Asn Ile Gly Ile
Asn Ile Gly Leu
Asn Ile Ile Gly
Asn Ile Leu Gly
Asn Ile Val Ala
Asn Leu Ala Val
Asn Leu Gly Ile
Asn Leu Gly Leu
Asn Leu Ile Gly
Asn Leu Leu Gly
Asn Leu Val Ala
Asn Val Ala Ile
Asn Val Ala Leu
Asn Val Ile Ala
Asn Val Leu Ala
Pro Ala Lys Thr
Pro Ala Thr Lys
Pro Lys Ala Thr
Pro Lys Thr Ala
Pro Thr Ala Lys
Pro Thr Lys Ala
Gln Ala Val Val
Gln Gly Ile Val
Gln Gly Leu Val
Gln Gly Val Ile
Gln Gly Val Leu
Gln Ile Gly Val
Gln Ile Val Gly
Gln Leu Gly Val
Gln Leu Val Gly
Gln Val Ala Val
Gln Val Gly Ile
Gln Val Gly Leu
Gln Val Ile Gly
Gln Val Leu Gly
Gln Val Val Ala
Arg Ala Ala Val
Arg Ala Gly Ile
Arg Ala Gly Leu
Arg Ala Ile Gly
Arg Ala Leu Gly
Arg Ala Val Ala
Arg Gly Ala Ile
Arg Gly Ala Leu
Arg Gly Ile Ala
Arg Gly Leu Ala
Arg Ile Ala Gly
Arg Ile Gly Ala
Arg Leu Ala Gly
Arg Leu Gly Ala
Arg Val Ala Ala
Thr Ala Lys Pro
Thr Ala Pro Lys
Thr Lys Ala Pro
Thr Lys Pro Ala
Thr Pro Ala Lys
Thr Pro Lys Ala
Val Ala Ala Arg
Val Ala Ile Asn
Val Ala Lys Val
C19H37N5O5 (415.27945520000003)
Val Ala Leu Asn
Val Ala Asn Ile
Val Ala Asn Leu
Val Ala Gln Val
Val Ala Arg Ala
Val Ala Val Lys
C19H37N5O5 (415.27945520000003)
Val Ala Val Gln
Val Gly Ile Lys
C19H37N5O5 (415.27945520000003)
Val Gly Ile Gln
Val Gly Lys Ile
C19H37N5O5 (415.27945520000003)
Val Gly Lys Leu
C19H37N5O5 (415.27945520000003)
Val Gly Leu Lys
C19H37N5O5 (415.27945520000003)
Val Gly Leu Gln
Val Gly Gln Ile
Val Gly Gln Leu
Val Ile Ala Asn
Val Ile Gly Lys
C19H37N5O5 (415.27945520000003)
Val Ile Gly Gln
Val Ile Lys Gly
C19H37N5O5 (415.27945520000003)
Val Ile Asn Ala
Val Ile Gln Gly
Val Lys Ala Val
C19H37N5O5 (415.27945520000003)
Val Lys Gly Ile
C19H37N5O5 (415.27945520000003)
Val Lys Gly Leu
C19H37N5O5 (415.27945520000003)
Val Lys Ile Gly
C19H37N5O5 (415.27945520000003)
Val Lys Leu Gly
C19H37N5O5 (415.27945520000003)
Val Lys Val Ala
C19H37N5O5 (415.27945520000003)
Val Leu Ala Asn
Val Leu Gly Lys
C19H37N5O5 (415.27945520000003)
Val Leu Gly Gln
Val Leu Lys Gly
C19H37N5O5 (415.27945520000003)
Val Leu Asn Ala
Val Leu Gln Gly
Val Asn Ala Ile
Val Asn Ala Leu
Val Asn Ile Ala
Val Asn Leu Ala
Val Gln Ala Val
Val Gln Gly Ile
Val Gln Gly Leu
Val Gln Ile Gly
Val Gln Leu Gly
Val Gln Val Ala
Val Arg Ala Ala
Val Val Ala Lys
C19H37N5O5 (415.27945520000003)
Val Val Ala Gln
Val Val Lys Ala
C19H37N5O5 (415.27945520000003)
Val Val Gln Ala
ethyl amide
C25H37NO4 (415.27224420000005)
(5E)-BiMatoprost
C25H37NO4 (415.27224420000005)
(R)-3-(2-(benzyloxy)-5-methylphenyl)-N,N-diisopropyl-3-phenylpropan-1-amine
N-(3,4-Diethyloxy)phenylethyl-3,4-diethyloxyphenyl acetamide
C24H33NO5 (415.23586080000007)
N-[(1S)-2-[(1S,3S,5S)-3-Cyano-2-azabicyclo[3.1.0]hex-2-yl]-1-(3-hydroxytricyclo[3.3.1.13,7]dec-1-yl)-2-oxoethyl]carbamic acid 1,1-dimethylethyl ester
C23H33N3O4 (415.2470938000001)
Piericidin A
C25H37NO4 (415.27224420000005)
A member of the class of monohydroxypyridines that acts as an irreversible mitochondrial Complex I inhibitor that strongly associates with ubiquinone binding sites in both mitochondrial and bacterial forms of NADH:ubiquinone oxidoreductase D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents
TNF Protease Inhibitor 2
C19H37N5O5 (415.27945520000003)
Ciliatamide B
A lipopeptide that contains N-methylphenylalanine and lysine as the amino acid residues linked to a octanoyl moiety via an amide linkage (the R,R stereoisomer). It is isolated from the deep sea sponge Aaptos ciliata and exhibits antileishmanial and moderate cytotoxicity towards HeLa cells.
A Disubstituted Succinyl Caprolactam Hydroxymate Mmp3inhibitor
N-[[4-(2-propan-2-yl-5-pyridin-4-ylpyrimidin-4-yl)cyclohexyl]methyl]pyridine-3-carboxamide
(Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((R,E)-3-hydroxy-5-phenylpent-1-en-1-yl)cyclopentyl)-N-ethylhept-5-enamide
C25H37NO4 (415.27224420000005)
2-[[(4E,7E,10E,13E,16E,19E)-docosa-4,7,10,13,16,19-hexaenoyl]amino]-3-hydroxypropanoic acid
C25H37NO4 (415.27224420000005)
Hippolide A
C25H37NO4 (415.27224420000005)
A natural product found in Hippospongia lachne.
smenospongines C
C24H33NO5 (415.23586080000007)
A sesquiterpenoid isolated from the marine sponge Dactylospongia elegans.
(Z)-7-[(1R,2R,3R,5S)-3,5-Dihydroxy-2-[(E)-3-hydroxy-5-phenylpent-1-enyl]cyclopentyl]-N-ethylhept-5-enamide
C25H37NO4 (415.27224420000005)
Phomacin C
C25H37NO4 (415.27224420000005)
A cytochalasin isolated from a fungus Phoma sp. that has been shown to possess potent inhibitory activity against HT-29 colonic adenocarcinoma cells.
(2R)-3-[[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]amino]-2-[2-[3-(trifluoromethyl)phenyl]ethylamino]-1-propanol
(1R,4R,5R,5S,8S)-1-methyl-5-(2-methylpropyl)-4-[(2S)-3-oxobutan-2-yl]spiro[2-oxatricyclo[6.4.1.04,13]tridec-4(13)-ene-5,3-pyrrolidine]-2,3,6-trione
C24H33NO5 (415.23586080000007)
[1-[3-(4-Methylphenoxy)propyl]-4-piperidinyl]-diphenylmethanol
C28H33NO2 (415.25111580000004)
(1S,9R,10R,11R)-5-(cyclohexen-1-yl)-12-ethyl-10-(hydroxymethyl)-N-(2-methoxyethyl)-6-oxo-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide
C23H33N3O4 (415.2470938000001)
(1R,9S,10S,11S)-5-(cyclohexen-1-yl)-12-ethyl-10-(hydroxymethyl)-N-(2-methoxyethyl)-6-oxo-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide
C23H33N3O4 (415.2470938000001)
(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-8-(4-methylpent-1-ynyl)-2-[[methyl(propyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one
(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-8-(4-methylpent-1-ynyl)-2-[[methyl(propyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one
(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-8-(4-methylpent-1-ynyl)-2-[[methyl(propyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one
N-[[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-8-(3-methylbut-1-ynyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylpropanamide
C23H33N3O4 (415.2470938000001)
N-[[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-8-(3-methylbut-1-ynyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylpropanamide
C23H33N3O4 (415.2470938000001)
(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-8-(4-methylpent-1-ynyl)-2-[[methyl(propyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one
(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-8-(4-methylpent-1-ynyl)-2-[[methyl(propyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one
(2S,3S)-2-[[cyclopentylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-8-[(E)-prop-1-enyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one
N-[[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-8-(3-methylbut-1-ynyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylpropanamide
C23H33N3O4 (415.2470938000001)
N-[[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-8-(3-methylbut-1-ynyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylpropanamide
C23H33N3O4 (415.2470938000001)
N-[[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-8-(3-methylbut-1-ynyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylpropanamide
C23H33N3O4 (415.2470938000001)
N-[[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-8-(3-methylbut-1-ynyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylpropanamide
C23H33N3O4 (415.2470938000001)
16-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxy-3-oxohexadecanoate
(15R)-15-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxy-3-oxohexadecanoate
N-(R)-[2-(Hydroxyaminocarbonyl)methyl]-4-methylpentanoyl-L-t-butyl-alanyl-L-alanine, 2-aminoethyl Amide
C19H37N5O5 (415.27945520000003)
NA-Ser 22:6(4Z,7Z,10Z,13Z,16Z,19Z)
C25H37NO4 (415.27224420000005)
GSK163090
GSK163090 is a potent, selective and orally active 5-HT1A/1B/1D receptor antagonist with pKi values of 9.4/8.5/9.7, respectively. GSK163090 inhibits the functional activity of serotonin reuptake transporter (SerT) with a pKi value of 6.1. GSK163090 has antidepressant and anxiolytic activities[1].
(5s,7s,10as,13s,13as,14s,16ar)-5,16-dihydroxy-7,9,12,13-tetramethyl-14-(2-methylpropyl)-5h,6h,7h,8h,10ah,13h,13ah,14h-oxacyclododeca[2,3-d]isoindol-2-one
C25H37NO4 (415.27224420000005)
6-hydroxy-11-methyl-5-methylidene-12-oxo-16-oxa-13-azahexacyclo[9.6.3.2⁴,⁷.0¹,¹⁰.0²,⁷.0¹³,¹⁷]docosan-8-yl acetate
C24H33NO5 (415.23586080000007)
n-(2-hydroxy-4,5,6,7-tetrahydro-3h-azepin-3-yl)-2-(n-methyloctanamido)-3-phenylpropanimidic acid
(3z,5r)-3-{[(1s,2r,4ar,8s,8ar)-2-[(2s,3s)-2,3-dimethyloxiran-2-yl]-3,8-dimethyl-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl](hydroxy)methylidene}-5-isopropyl-1-methylpyrrolidine-2,4-dione
C25H37NO4 (415.27224420000005)
10,13-dihydroxy-1,5,6-trimethyl-8-(2-methylpropyl)-19-oxa-9-azapentacyclo[14.2.1.0²,¹⁴.0³,¹¹.0⁷,¹¹]nonadeca-4,9-diene-12,15-dione
C24H33NO5 (415.23586080000007)
(2r,3s,3as,5's,5as,7r,9ar,9bs)-2'-hydroxy-3-[(1e,3r)-3-hydroxybut-1-en-1-yl]-5'-[(1r)-1-hydroxyethyl]-7,9b-dimethyl-3,3a,5a,6,7,8,9,9a-octahydro-5'h-spiro[cyclopenta[a]naphthalene-2,3'-pyrrole]-1,4'-dione
C24H33NO5 (415.23586080000007)
(1s,2r,3r,6s,7r,8s,11r,13r,14r,16r)-10,13-dihydroxy-1,5,6-trimethyl-8-(2-methylpropyl)-19-oxa-9-azapentacyclo[14.2.1.0²,¹⁴.0³,¹¹.0⁷,¹¹]nonadeca-4,9-diene-12,15-dione
C24H33NO5 (415.23586080000007)
(1'r,3s,4r,5s,8's)-2-hydroxy-1'-methyl-5-(2-methylpropyl)-4-[(2s)-3-oxobutan-2-yl]-4,5-dihydro-2'-oxaspiro[pyrrole-3,5'-tricyclo[6.4.1.0⁴,¹³]tridecan]-4'(13')-ene-3',6'-dione
C24H33NO5 (415.23586080000007)
(3z,5r)-3-{[(1s,4ar,6s,8r,8ar)-2-[(2s,3s)-2,3-dimethyloxiran-2-yl]-6,8-dimethyl-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl](hydroxy)methylidene}-5-isopropyl-1-methylpyrrolidine-2,4-dione
C25H37NO4 (415.27224420000005)
(3z,5r)-3-{[(1as,2s,3s,3ar,4s,7ar,7br)-2-[(2e)-but-2-en-2-yl]-1a,4-dimethyl-octahydro-2h-naphtho[1,2-b]oxiren-3-yl](hydroxy)methylidene}-5-isopropyl-1-methylpyrrolidine-2,4-dione
C25H37NO4 (415.27224420000005)
2-[(9s,10r)-10-hydroxy-3,7,9,11-tetramethyltrideca-2,4,7,11-tetraen-1-yl]-5,6-dimethoxy-3-methylpyridin-4-ol
C25H37NO4 (415.27224420000005)
(1r,5r,8r,10s,11r,14s,16r,17s,18s)-7-(2-hydroxyethyl)-5-methyl-13-methylidene-6-oxo-9-oxa-7-azahexacyclo[8.6.2.2¹¹,¹⁴.0¹,⁸.0⁵,¹⁷.0¹¹,¹⁶]icosan-18-yl acetate
C24H33NO5 (415.23586080000007)
2-[(2e,5e,7e,9s,10r,11e)-10-hydroxy-3,7,9,11-tetramethyltrideca-2,5,7,11-tetraen-1-yl]-5,6-dimethoxy-3-methylpyridin-4-ol
C25H37NO4 (415.27224420000005)
2-[(2e,5e,7e,9r,10r,11e)-10-hydroxy-3,7,9,11-tetramethyltrideca-2,5,7,11-tetraen-1-yl]-5,6-dimethoxy-3-methylpyridin-4-ol
C25H37NO4 (415.27224420000005)
methyl 4-[(1e)-2-acetyl-4-oxotridec-1-en-1-yl]-6-propylpyridine-3-carboxylate
C25H37NO4 (415.27224420000005)
(1s,3s,5r,8s,9r,10s,11r,14r,16s,17r,18s,19s)-9,10,19-trihydroxy-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecan-3-yl 2-methylpropanoate
C24H33NO5 (415.23586080000007)
3-({5-[(1,2,4a-trimethyl-5-methylidene-hexahydro-2h-naphthalen-1-yl)methyl]-4-hydroxy-3,6-dioxocyclohexa-1,4-dien-1-yl}amino)propanoic acid
C24H33NO5 (415.23586080000007)
6,13,19-trihydroxy-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecan-15-yl 2-methylpropanoate
C24H33NO5 (415.23586080000007)
11,16,19-trihydroxy-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecan-13-yl 2-methylpropanoate
C24H33NO5 (415.23586080000007)
(2r,3s,4r,5r,6s)-2-{[(6e,8s,9s,10s,10ar)-10-hydroxy-7,7,8,10-tetramethyl-1,2,3,4,5,8,9,10a-octahydro-3-benzazocin-9-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol
(3s,3ar,4s,6as,10s,12s,15ar)-1,12-dihydroxy-10-(hydroxymethyl)-4,5,8-trimethyl-3-(2-methylpropyl)-3h,3ah,4h,6ah,9h,10h,11h,12h-cycloundeca[d]isoindol-15-one
C25H37NO4 (415.27224420000005)
8-(acetyloxy)-12-hydroxy-11-methyl-5-methylidene-13-azapentacyclo[9.3.3.2⁴,⁷.0¹,¹⁰.0²,⁷]nonadec-13-en-9-yl acetate
C24H33NO5 (415.23586080000007)
methyl 4-(2-acetyl-4-oxotridec-1-en-1-yl)-6-propylpyridine-3-carboxylate
C25H37NO4 (415.27224420000005)
2-[(2e,4e,7e,9s,10r,11e)-10-hydroxy-3,7,9,11-tetramethyltrideca-2,4,7,11-tetraen-1-yl]-5,6-dimethoxy-3-methylpyridin-4-ol
C25H37NO4 (415.27224420000005)
(2s)-4-[(1s,4ar,6s,8r,8ar)-2-[(2s,3s)-2,3-dimethyloxiran-2-yl]-6,8-dimethyl-1,2,4a,5,6,7,8,8a-octahydronaphthalene-1-carbonyl]-5-hydroxy-2-isopropyl-1-methyl-2h-pyrrol-3-one
C25H37NO4 (415.27224420000005)
3-{[2-(but-2-en-2-yl)-1a,4-dimethyl-octahydro-2h-naphtho[1,2-b]oxiren-3-yl](hydroxy)methylidene}-5-isopropyl-1-methylpyrrolidine-2,4-dione
C25H37NO4 (415.27224420000005)
9,10,19-trihydroxy-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecan-3-yl 2-methylpropanoate
C24H33NO5 (415.23586080000007)
3-{[2-(2,3-dimethyloxiran-2-yl)-3,8-dimethyl-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl](hydroxy)methylidene}-5-isopropyl-1-methylpyrrolidine-2,4-dione
C25H37NO4 (415.27224420000005)
2'-hydroxy-3-(3-hydroxybut-1-en-1-yl)-5'-(1-hydroxyethyl)-7,9b-dimethyl-3,3a,5a,6,7,8,9,9a-octahydro-5'h-spiro[cyclopenta[a]naphthalene-2,3'-pyrrole]-1,4'-dione
C24H33NO5 (415.23586080000007)
(1r,5r,8r,9r,11s,13r,14r,17r,18s,19r)-11,16,19-trihydroxy-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecan-13-yl 2-methylpropanoate
C24H33NO5 (415.23586080000007)
2-[(2e,5e,7e,9s,10r,11z)-10-hydroxy-3,7,9,11-tetramethyltrideca-2,5,7,11-tetraen-1-yl]-5,6-dimethoxy-3-methylpyridin-4-ol
C25H37NO4 (415.27224420000005)
(1r,5s,8r,9s,11s,13r,14r,16r,17r,18s,19r)-11,16,19-trihydroxy-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecan-13-yl 2-methylpropanoate
C24H33NO5 (415.23586080000007)
(2r,3s,3as,5'r,5as,7r,9ar,9bs)-2'-hydroxy-3-[(3r)-3-hydroxybut-1-en-1-yl]-5'-[(1r)-1-hydroxyethyl]-7,9b-dimethyl-3,3a,5a,6,7,8,9,9a-octahydro-5'h-spiro[cyclopenta[a]naphthalene-2,3'-pyrrole]-1,4'-dione
C24H33NO5 (415.23586080000007)
(1r,5r,8r,9s,11s,13r,14r,16r,17r,18s,19r)-11,16,19-trihydroxy-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecan-13-yl 2-methylpropanoate
C24H33NO5 (415.23586080000007)
(1s,5r,8r,10s,11r,12r,14s,16s,17r)-3-(2-hydroxyethyl)-5-methyl-13-methylidene-4-oxo-9-oxa-3-azahexacyclo[8.6.2.2¹¹,¹⁴.0¹,⁸.0⁵,¹⁷.0¹¹,¹⁶]icosan-12-yl acetate
C24H33NO5 (415.23586080000007)
(1s,2r,3r,6s,7r,8s,11r,14s,15r,17r)-10-hydroxy-17-(hydroxymethyl)-1,5,6-trimethyl-8-(2-methylpropyl)-19-oxa-9-azapentacyclo[13.3.1.0²,¹⁴.0³,¹¹.0⁷,¹¹]nonadeca-4,9-dien-12-one
C25H37NO4 (415.27224420000005)
(1s,5s,6r,8r,9s,11r,13r,14s,15s,16r,17s,18s,19r)-6,13,19-trihydroxy-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecan-15-yl 2-methylpropanoate
C24H33NO5 (415.23586080000007)
(2r,3s,4r,5r,6s)-2-{[(8s,9s,10s,10ar)-10-hydroxy-7,7,8,10-tetramethyl-1,2,3,4,5,8,9,10a-octahydro-3-benzazocin-9-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol
(2s)-n-[(3s)-2-hydroxy-4,5,6,7-tetrahydro-3h-azepin-3-yl]-2-(n-methyloctanamido)-3-phenylpropanimidic acid
(3s)-5-hydroxy-3-[(2r,6s)-6-hydroxy-5-[(3e,7e)-4,8,12-trimethyltrideca-3,7,11-trien-1-yl]-3,6-dihydro-2h-pyran-2-yl]-3,4-dihydropyrrol-2-one
C25H37NO4 (415.27224420000005)
(2r)-n-[(3r)-2-hydroxy-4,5,6,7-tetrahydro-3h-azepin-3-yl]-2-(n-methyloctanamido)-3-phenylpropanimidic acid
(1r,5r,8r,10s,14s,16r,17s,18s)-7-(2-hydroxyethyl)-5-methyl-13-methylidene-6-oxo-9-oxa-7-azahexacyclo[8.6.2.2¹¹,¹⁴.0¹,⁸.0⁵,¹⁷.0¹¹,¹⁶]icosan-18-yl acetate
C24H33NO5 (415.23586080000007)
(1r,5r,8r,10r,11r,12s,14s,16r,17s)-7-(2-hydroxyethyl)-5-methyl-13-methylidene-6-oxo-9-oxa-7-azahexacyclo[8.6.2.2¹¹,¹⁴.0¹,⁸.0⁵,¹⁷.0¹¹,¹⁶]icosan-12-yl acetate
C24H33NO5 (415.23586080000007)
(1r,2s,4s,7r,8s,9s,10s,11r,12r)-8-(acetyloxy)-12-hydroxy-11-methyl-5-methylidene-13-azapentacyclo[9.3.3.2⁴,⁷.0¹,¹⁰.0²,⁷]nonadec-13-en-9-yl acetate
C24H33NO5 (415.23586080000007)
2-(10-hydroxy-3,7,9,11-tetramethyltrideca-2,5,7,11-tetraen-1-yl)-5,6-dimethoxy-3-methylpyridin-4-ol
C25H37NO4 (415.27224420000005)
2-hydroxy-1'-methyl-5-(2-methylpropyl)-4-(3-oxobutan-2-yl)-4,5-dihydro-2'-oxaspiro[pyrrole-3,5'-tricyclo[6.4.1.0⁴,¹³]tridecan]-4'(13')-ene-3',6'-dione
C24H33NO5 (415.23586080000007)
1,12-dihydroxy-10-(hydroxymethyl)-4,5,8-trimethyl-3-(2-methylpropyl)-3h,3ah,4h,6ah,9h,10h,11h,12h-cycloundeca[d]isoindol-15-one
C25H37NO4 (415.27224420000005)
(1s,3s,5s,8s,9r,10s,11r,14r,16s,17r,18s,19r)-9,10,19-trihydroxy-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecan-3-yl 2-methylpropanoate
C24H33NO5 (415.23586080000007)
(3s)-5-hydroxy-3-[(2r,6s)-6-hydroxy-5-[(7e)-4,8,12-trimethyltrideca-3,7,11-trien-1-yl]-3,6-dihydro-2h-pyran-2-yl]-3,4-dihydropyrrol-2-one
C25H37NO4 (415.27224420000005)